Akademik Veri Yönetim Sistemi
GYNECOLOGY AND MINIMALLY INVASIVE THERAPY, cilt.1, sa.1, ss.1-7, 2024 (ESCI)
Objective: We investigated the relationship between the degree of fibrosis and endometrial cancer (EC) by calculating the fibrosis‐4 (FIB‐4) score, a noninvasive marker for measuring the severity of liver fibrosis.
Materials and Methods: Liver function tests, platelet (PLT) values, abdominal ultrasound, and magnetic resonance imaging reports were analyzed retrospectively before, after, and at diagnosis in patients with EC.
Results: The study included 38 patients diagnosed with EC. The median FIB‐4 score was calculated as 1.15 (minimum: 0.46–maximum: 3.72). When endometroid (type 1 EC) and nonendometroid (type 2 EC) were compared, the FIB‐4 score was higher in type one patients (1.16 [0.46–3.72] and 1.01 [0.53–2.96], respectively). However, there was no significant difference between the two groups (P = 0.961). There was no significant difference between the groups in terms of aspartate aminotransferase, alanine aminotransferase, and PLT parameters before diagnosis, at the time of diagnosis, and after treatment. Gamma‐glutamyl transferase (GGT) level was significantly higher in the type 1 group in the prediagnosis period (P = 0.016). In the posttreatment period, GGT was higher in the type 2 group (P = 0.020). For PLT level, there was a statistically significant difference between all three periods only in the type 1 group (P < 0.001).
Conclusion: FIB‐4 score was higher in patients with type 1 EC, which is more associated with obesity and hormones. In addition, prediagnostic values of GGT and PLT were statistically significantly higher in the type 1 group. Our study needs further studies to support FIB‐4 score and biochemical GGT and PLT as biochemical markers in patients with type 1 EC.
Keywords: Endometrial cancer, fatty liver disease, fibrosis‐4 score, gamma‐glutamyl transferase, liver fibrosis, new cancer control strategy, platelet.